Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone Source: Eur Respir J 2001; 18: 262-268 Year: 2001
Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids Source: Eur Respir J 2002; 19: 182-191 Year: 2002
Sequential flexible therapy with formoterol (Foradil®) plus budesonide (Miflonide®) versus a fixed combination of salmeterol and fluticasone (Seretide®) in asthma self-management Source: Eur Respir J 2002; 20: Suppl. 38, 388s Year: 2002
Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Source: Eur Respir J 2005; 26: 819-828 Year: 2005
Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 386s Year: 2002
Cost-effectiveness of budesonide and formoterol in a single inhaler compared to fluticasone in the treatment of asthma Source: Eur Respir J 2001; 18: Suppl. 33, 157s Year: 2001
Efficacy and safety of the new beclomethasone dipropionate/formoterol combination vs. fluticasone propionate/salmeterol pMDIs in moderate to severe persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 205s Year: 2006
Safety of formoterol by Turbuhaler(R) as reliever medication compared with terbutaline in moderate asthma Source: Eur Respir J 2002; 20: 859-866 Year: 2002
Short-acting bronchodilator and oral steroid use in asthma patients prescribed either concurrent beclometasone and salmeterol or combined salmeterol/fluticasone Source: Eur Respir J 2004; 24: Suppl. 48, 309s Year: 2004
Low-dose single-inhaler budesonide/formoterol administered once daily is effective in mild-persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 158s Year: 2001
Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012
QVAR pMDI is more cost-effective than fluticasone propionate (FP) or CFC-beclometasone dipropionate (BDP) PMDI in a real-life asthmatic population receiving an increase in ICS dose Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care Year: 2009
Single inhaler therapy (SiT) with budesonide/formoterol (BUD/FM) is effective in asthma control Source: Eur Respir J 2005; 26: Suppl. 49, 124s Year: 2005
Effects of budesonide/formoterol combination therapy versus budesonide on airway dimensions in asthma Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases Year: 2012
A comparison of the efficacy of salmeterol/fluticasone propionate combination (SF) with beclometasone dipropionate (BDP) delivered via metered dose inhaler (MDI) in patients not well controlled on bronchodilators alone Source: Eur Respir J 2001; 18: Suppl. 33, 53s Year: 2001
Combination therapy with maintenance budesonide and formoterol in COPD Source: Eur Respir J 2004; 24: 1070 Year: 2004
Once-daily, high-dose inhaled fluticasone propionate and salmeterol in patients having moderate asthma Source: Eur Respir J 2004; 24: Suppl. 48, 125s Year: 2004
Initial maintenance therapy with fluticasone propionate/ salmeterol combination product provides superior asthma control versus montelukast or fluticasone propionate alone Source: Eur Respir J 2002; 20: Suppl. 38, 386s Year: 2002
Combination therapy with salmeterol and fluticasone propionate (SFC) is more effective than salmeterol (SAL) alone in reducing exacerbations of COPD Source: Eur Respir J 2005; 26: Suppl. 49, 292s Year: 2005
Plume characteristics of fluticasone propionate/formoterol pMDI compared with fluticasone propionate/salmeterol pMDI Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013